DD296960A5 - Therapreutisches mittel - Google Patents
Therapreutisches mittel Download PDFInfo
- Publication number
- DD296960A5 DD296960A5 DD90340234A DD34023490A DD296960A5 DD 296960 A5 DD296960 A5 DD 296960A5 DD 90340234 A DD90340234 A DD 90340234A DD 34023490 A DD34023490 A DD 34023490A DD 296960 A5 DD296960 A5 DD 296960A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- chymopapain
- added
- minutes
- aqueous
- solution
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 108090001069 Chymopapain Proteins 0.000 claims abstract description 232
- 229960002976 chymopapain Drugs 0.000 claims abstract description 224
- ISWQCIVKKSOKNN-UHFFFAOYSA-L Tiron Chemical compound [Na+].[Na+].OC1=CC(S([O-])(=O)=O)=CC(S([O-])(=O)=O)=C1O ISWQCIVKKSOKNN-UHFFFAOYSA-L 0.000 claims abstract description 222
- 238000000034 method Methods 0.000 claims abstract description 64
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 41
- 238000001042 affinity chromatography Methods 0.000 claims abstract description 31
- 238000000746 purification Methods 0.000 claims abstract description 30
- 239000011159 matrix material Substances 0.000 claims abstract description 27
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 24
- 239000003480 eluent Substances 0.000 claims abstract description 19
- 230000008569 process Effects 0.000 claims abstract description 17
- 239000012504 chromatography matrix Substances 0.000 claims abstract description 15
- 230000002441 reversible effect Effects 0.000 claims abstract description 10
- 239000007864 aqueous solution Substances 0.000 claims abstract description 8
- 125000006850 spacer group Chemical group 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 115
- 239000000203 mixture Substances 0.000 claims description 109
- 238000001556 precipitation Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 abstract description 33
- 238000010828 elution Methods 0.000 abstract description 16
- 238000011534 incubation Methods 0.000 abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 8
- 238000004140 cleaning Methods 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 129
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 109
- 230000000694 effects Effects 0.000 description 84
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 68
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 66
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- 108010092515 glycyl endopeptidase Proteins 0.000 description 62
- 235000018102 proteins Nutrition 0.000 description 50
- 102000004169 proteins and genes Human genes 0.000 description 50
- 108090000623 proteins and genes Proteins 0.000 description 50
- 239000000872 buffer Substances 0.000 description 47
- 238000003756 stirring Methods 0.000 description 42
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 41
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 39
- 238000002390 rotary evaporation Methods 0.000 description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 36
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 31
- 239000002904 solvent Substances 0.000 description 31
- 238000001914 filtration Methods 0.000 description 28
- 102000004190 Enzymes Human genes 0.000 description 27
- 108090000790 Enzymes Proteins 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 229940088598 enzyme Drugs 0.000 description 27
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 25
- 238000004458 analytical method Methods 0.000 description 25
- 239000004816 latex Substances 0.000 description 25
- 229920000126 latex Polymers 0.000 description 25
- 235000009467 Carica papaya Nutrition 0.000 description 24
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 23
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 108090000391 Caricain Proteins 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
- 229920002684 Sepharose Polymers 0.000 description 20
- 239000011734 sodium Substances 0.000 description 20
- 239000011780 sodium chloride Substances 0.000 description 20
- 239000003054 catalyst Substances 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 19
- 229960002433 cysteine Drugs 0.000 description 19
- 239000012074 organic phase Substances 0.000 description 19
- 239000000499 gel Substances 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 108090000526 Papain Proteins 0.000 description 17
- 239000004365 Protease Substances 0.000 description 17
- 235000019834 papain Nutrition 0.000 description 17
- 229940055729 papain Drugs 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 235000017281 sodium acetate Nutrition 0.000 description 16
- 239000000758 substrate Substances 0.000 description 16
- 239000000427 antigen Substances 0.000 description 15
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 15
- 235000018417 cysteine Nutrition 0.000 description 15
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 15
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 14
- 241000219173 Carica Species 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 108050004038 cystatin Proteins 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 238000003916 acid precipitation Methods 0.000 description 13
- 108010041102 azocasein Proteins 0.000 description 13
- 238000005277 cation exchange chromatography Methods 0.000 description 13
- 238000000502 dialysis Methods 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000001632 sodium acetate Substances 0.000 description 12
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 11
- 229940105325 3-dimethylaminopropylamine Drugs 0.000 description 11
- 108010005843 Cysteine Proteases Proteins 0.000 description 11
- 102000005927 Cysteine Proteases Human genes 0.000 description 11
- 102000035195 Peptidases Human genes 0.000 description 11
- 108091005804 Peptidases Proteins 0.000 description 11
- 239000003638 chemical reducing agent Substances 0.000 description 11
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 11
- -1 for example Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 235000019833 protease Nutrition 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 240000006432 Carica papaya Species 0.000 description 10
- XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 230000000951 immunodiffusion Effects 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000001488 sodium phosphate Substances 0.000 description 9
- 229910000162 sodium phosphate Inorganic materials 0.000 description 9
- 238000004448 titration Methods 0.000 description 9
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 9
- 108010016626 Dipeptides Proteins 0.000 description 8
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 150000007659 semicarbazones Chemical class 0.000 description 8
- 239000001509 sodium citrate Substances 0.000 description 8
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 8
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 7
- XHQYBDSXTDXSHY-UHFFFAOYSA-N Semicarbazide hydrochloride Chemical compound Cl.NNC(N)=O XHQYBDSXTDXSHY-UHFFFAOYSA-N 0.000 description 7
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 7
- 229910052753 mercury Inorganic materials 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- TVSCFMXJYNZEER-UHFFFAOYSA-N 7-methoxy-11a-methyl-1,9b,10,11-tetrahydronaphtho[1,2-g]indole Chemical compound C1CC2(C)CC=NC2=C2C=CC3=CC(OC)=CC=C3C21 TVSCFMXJYNZEER-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000005341 cation exchange Methods 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
- 239000012149 elution buffer Substances 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical group [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 5
- 239000000356 contaminant Substances 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 150000002923 oximes Chemical class 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 4
- KYNFOMQIXZUKRK-UHFFFAOYSA-N 2,2'-dithiodiethanol Chemical compound OCCSSCCO KYNFOMQIXZUKRK-UHFFFAOYSA-N 0.000 description 4
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 4
- 102100028007 Cystatin-SA Human genes 0.000 description 4
- 101710144510 Cysteine proteinase inhibitor Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000004201 L-cysteine Substances 0.000 description 4
- 235000013878 L-cysteine Nutrition 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000009739 binding Methods 0.000 description 4
- 230000037029 cross reaction Effects 0.000 description 4
- 229960001305 cysteine hydrochloride Drugs 0.000 description 4
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 4
- 239000011928 denatured alcohol Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 4
- HAEPBEMBOAIUPN-UHFFFAOYSA-L sodium tetrathionate Chemical compound O.O.[Na+].[Na+].[O-]S(=O)(=O)SSS([O-])(=O)=O HAEPBEMBOAIUPN-UHFFFAOYSA-L 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- BHANCCMWYDZQOR-UHFFFAOYSA-N 2-(methyldisulfanyl)pyridine Chemical compound CSSC1=CC=CC=N1 BHANCCMWYDZQOR-UHFFFAOYSA-N 0.000 description 3
- 101000658124 Apomastus schlingeri Mu-cyrtautoxin-As1a Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000424725 Heide Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 101000986389 Spodoptera exigua Paralytic peptide 3 Proteins 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000012062 aqueous buffer Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000003729 cation exchange resin Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 150000002019 disulfides Chemical class 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229960000224 mersalyl Drugs 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- QGGPRJRKWYRGKR-UHFFFAOYSA-M sodium;[3-[[2-(carboxylatomethoxy)benzoyl]amino]-2-methoxypropyl]mercury;hydrate Chemical group O.[Na+].COC(C[Hg])CNC(=O)C1=CC=CC=C1OCC([O-])=O QGGPRJRKWYRGKR-UHFFFAOYSA-M 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- PCDWFBFHIIKIPM-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole-2-sulfonic acid Chemical compound C1=CC=C2N(CC)C(S(O)(=O)=O)SC2=C1 PCDWFBFHIIKIPM-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000015833 Cystatin Human genes 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940023913 cation exchange resins Drugs 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 229940079919 digestives enzyme preparation Drugs 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960002523 mercuric chloride Drugs 0.000 description 2
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 150000002994 phenylalanines Chemical class 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000005201 scrubbing Methods 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- CGWBIHLHAGNJCX-UHFFFAOYSA-N 2-butylguanidine Chemical compound CCCCNC(N)=N CGWBIHLHAGNJCX-UHFFFAOYSA-N 0.000 description 1
- VLQBSKLZRSUMTJ-UHFFFAOYSA-N 2-methylsulfanylpyridine Chemical compound CSC1=CC=CC=N1 VLQBSKLZRSUMTJ-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108090000252 Histolysain Proteins 0.000 description 1
- 101000898449 Homo sapiens Cathepsin B Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- QIJRTFXNRTXDIP-JIZZDEOASA-N L-cysteine hydrochloride hydrate Chemical compound O.Cl.SC[C@H](N)C(O)=O QIJRTFXNRTXDIP-JIZZDEOASA-N 0.000 description 1
- 101000952180 Morus alba Mulatexin Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010042618 Surgical procedure repeated Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- PMWPVSHTZHBVBG-QMMMGPOBSA-N [[(2s)-2-amino-3-phenylpropanoyl]amino]urea Chemical compound NC(=O)NN=C(O)[C@@H](N)CC1=CC=CC=C1 PMWPVSHTZHBVBG-QMMMGPOBSA-N 0.000 description 1
- BFCAHCWCGRBTOZ-YFKPBYRVSA-N [[(2s)-2-amino-4-methylpentanoyl]amino]urea Chemical compound CC(C)C[C@H](N)C(O)=NNC(N)=O BFCAHCWCGRBTOZ-YFKPBYRVSA-N 0.000 description 1
- NGCQTBKWXZOLIE-REOHCLBHSA-N [[(2s)-2-aminopropanoyl]amino]urea Chemical compound C[C@H](N)C(O)=NNC(N)=O NGCQTBKWXZOLIE-REOHCLBHSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000053907 human CTSB Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- UDGSVBYJWHOHNN-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCN UDGSVBYJWHOHNN-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 208000013441 ocular lesion Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- YFZOUMNUDGGHIW-UHFFFAOYSA-M p-chloromercuribenzoic acid Chemical compound OC(=O)C1=CC=C([Hg]Cl)C=C1 YFZOUMNUDGGHIW-UHFFFAOYSA-M 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- LJPYJRMMPVFEKR-UHFFFAOYSA-N prop-2-ynylurea Chemical compound NC(=O)NCC#C LJPYJRMMPVFEKR-UHFFFAOYSA-N 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- OYGWLRRBJCSNDB-ZDUSSCGKSA-N tert-butyl n-[(2s)-1-(cyanomethylamino)-1-oxo-3-phenylpropan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](C(=O)NCC#N)CC1=CC=CC=C1 OYGWLRRBJCSNDB-ZDUSSCGKSA-N 0.000 description 1
- NYBWUHOMYZZKOR-UHFFFAOYSA-N tes-adt Chemical class C1=C2C(C#C[Si](CC)(CC)CC)=C(C=C3C(SC=C3)=C3)C3=C(C#C[Si](CC)(CC)CC)C2=CC2=C1SC=C2 NYBWUHOMYZZKOR-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- ORQXBVXKBGUSBA-QMMMGPOBSA-N β-cyclohexyl-alanine Chemical compound OC(=O)[C@@H](N)CC1CCCCC1 ORQXBVXKBGUSBA-QMMMGPOBSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Detergent Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB898909836A GB8909836D0 (en) | 1989-04-28 | 1989-04-28 | Therapeutic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD296960A5 true DD296960A5 (de) | 1991-12-19 |
Family
ID=10655944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD90340234A DD296960A5 (de) | 1989-04-28 | 1990-04-27 | Therapreutisches mittel |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US5380656A (cs) |
| EP (1) | EP0470136B1 (cs) |
| JP (1) | JPH04506003A (cs) |
| KR (1) | KR920701241A (cs) |
| CN (1) | CN1047340A (cs) |
| AT (1) | ATE107660T1 (cs) |
| AU (1) | AU631641B2 (cs) |
| BG (1) | BG60916B1 (cs) |
| CA (1) | CA2056402C (cs) |
| DD (1) | DD296960A5 (cs) |
| DE (1) | DE69010199T2 (cs) |
| DK (1) | DK0470136T3 (cs) |
| EG (1) | EG19583A (cs) |
| ES (1) | ES2055427T3 (cs) |
| FI (1) | FI914995A0 (cs) |
| GB (1) | GB8909836D0 (cs) |
| GR (1) | GR1001011B (cs) |
| HR (1) | HRP930700A2 (cs) |
| HU (2) | HUT58345A (cs) |
| IE (1) | IE64351B1 (cs) |
| IL (1) | IL94227A (cs) |
| IN (2) | IN170683B (cs) |
| LT (1) | LT3827B (cs) |
| LV (1) | LV10200B (cs) |
| MX (1) | MX20503A (cs) |
| NO (1) | NO914206L (cs) |
| NZ (1) | NZ233475A (cs) |
| PL (1) | PL166810B1 (cs) |
| PT (1) | PT93921B (cs) |
| RO (1) | RO112032B1 (cs) |
| RU (1) | RU2074891C1 (cs) |
| WO (1) | WO1990013561A1 (cs) |
| YU (1) | YU87090A (cs) |
| ZA (1) | ZA903228B (cs) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8909836D0 (en) * | 1989-04-28 | 1989-06-14 | Boots Co Plc | Therapeutic agent |
| EP0572547A1 (en) * | 1991-02-22 | 1993-12-08 | The Du Pont Merck Pharmaceutical Company | SUBSTITUTED $g(a)-AMINOALDEHYDES AND DERIVATIVES |
| CA2061861A1 (en) * | 1991-03-04 | 1992-09-05 | Jonathan Duvick | Plant polypeptides with inhibitory activity towards pathogenic microorganisms |
| CN1060519C (zh) * | 1991-05-09 | 2001-01-10 | 广西亚热带作物研究所 | 桄榔植物蛋白酶的提取方法 |
| AU668110B2 (en) * | 1991-10-14 | 1996-04-26 | Cash Engineering Research Pty Ltd | Inlet control combination for a compressor system |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| WO1994028012A1 (en) * | 1993-05-28 | 1994-12-08 | Warner-Lambert Company | Hydroxamate inhibitors of endothelin converting enzyme |
| WO2000051998A1 (en) | 1999-03-02 | 2000-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cathepsin s |
| IL145429A0 (en) | 1999-03-15 | 2002-06-30 | Axys Pharm Inc | N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same |
| US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
| US6703040B2 (en) | 2000-01-11 | 2004-03-09 | Intralytix, Inc. | Polymer blends as biodegradable matrices for preparing biocomposites |
| JP4512038B2 (ja) * | 2002-12-25 | 2010-07-28 | 小森 博達 | 椎間板変性治療剤 |
| US7169405B2 (en) * | 2003-08-06 | 2007-01-30 | Warsaw Orthopedic, Inc. | Methods and devices for the treatment of intervertebral discs |
| JP2008505887A (ja) * | 2004-07-06 | 2008-02-28 | 幾夫 森本 | パパイヤ抽出液を含む癌の予防、治療、または改善のための組成物 |
| CN1320111C (zh) * | 2004-08-09 | 2007-06-06 | 王美岭 | 一种制备木瓜凝乳酶的方法 |
| US20060241566A1 (en) * | 2005-04-11 | 2006-10-26 | Orthox, Llc | Nucleus Extraction from Spine Intervertebral Disc |
| US8642060B2 (en) * | 2006-04-24 | 2014-02-04 | Warsaw Orthopedic, Inc. | Controlled release systems and methods for osteal growth |
| US7771414B2 (en) * | 2006-04-24 | 2010-08-10 | Warsaw Orthopedic, Inc. | Controlled release devices for therapeutic treatments of spinal discs |
| US8642059B2 (en) | 2006-04-24 | 2014-02-04 | Warsaw Orthopedic, Inc. | Controlled release systems and methods for intervertebral discs |
| US7879027B2 (en) * | 2006-04-24 | 2011-02-01 | Warsaw Orthopedic, Inc. | Controlled release devices for fusion of osteal structures |
| US20070265633A1 (en) * | 2006-05-11 | 2007-11-15 | Moon Jon K | Implement and method to extract nucleus from spine intervertebral disc |
| US8257938B2 (en) * | 2009-02-27 | 2012-09-04 | Medical Diagnostic Laboratories, Llc | Hemolysin and its protein fragments in sero-detection of Anaplasma phagocytophilum |
| WO2013038936A1 (ja) * | 2011-09-13 | 2013-03-21 | タカラバイオ株式会社 | ペルオキシダーゼ反応の停止方法及び反応停止剤 |
| US9375519B2 (en) | 2012-06-25 | 2016-06-28 | Surmodics, Inc. | Bioerodable poly(etheresteramides) and medical article uses |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE270723C (cs) * | ||||
| US2313875A (en) * | 1940-12-17 | 1943-03-16 | Eugene F Jansen | Proteolytic enzyme process |
| US3320131A (en) * | 1964-10-23 | 1967-05-16 | Baxter Laboratories Inc | Method for the treatment of herniation of intervertebral discs |
| US3558433A (en) * | 1967-11-07 | 1971-01-26 | Baxter Laboratories Inc | Process for purification of chymopapain |
| YU40433B (en) * | 1975-02-20 | 1986-02-28 | Lek Tovarna Farmacevtskih | Process for obtaining pure, proteolytically active anzymes |
| DE3212846A1 (de) | 1981-04-13 | 1982-11-04 | Sintokogio, Ltd., Nagoya, Aichi | Apparat und verfahren zum herstellen eines kerns |
| US4719108A (en) * | 1981-05-13 | 1988-01-12 | Smith Laboratories, Inc. | Chymopapain composition and method for its use |
| US4439423A (en) * | 1981-05-13 | 1984-03-27 | Smith Laboratories, Inc. | Chymopapain and method for its use |
| US4374926A (en) * | 1981-05-13 | 1983-02-22 | Smith Laboratories, Inc. | Method for the production of improved chymopapain |
| DE3278934D1 (en) * | 1981-05-13 | 1988-09-29 | Flint Lab Inc | Improved chymopapain and method for its production and use |
| WO1984000365A1 (en) * | 1982-07-19 | 1984-02-02 | Nat Res Dev | Synthetic peptides and their preparation |
| GB2156821A (en) * | 1984-04-03 | 1985-10-16 | Simmons James W | Process for purifying chymopapain |
| HU196624B (en) * | 1986-12-08 | 1988-12-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing chymopapain with high specific activity |
| GB8909836D0 (en) * | 1989-04-28 | 1989-06-14 | Boots Co Plc | Therapeutic agent |
-
1989
- 1989-04-28 GB GB898909836A patent/GB8909836D0/en active Pending
-
1990
- 1990-04-26 IN IN327/MAS/90A patent/IN170683B/en unknown
- 1990-04-26 GR GR900100315A patent/GR1001011B/el unknown
- 1990-04-27 ZA ZA903228A patent/ZA903228B/xx unknown
- 1990-04-27 JP JP2506560A patent/JPH04506003A/ja active Pending
- 1990-04-27 IE IE153890A patent/IE64351B1/en not_active IP Right Cessation
- 1990-04-27 CN CN90103907A patent/CN1047340A/zh active Pending
- 1990-04-27 CA CA002056402A patent/CA2056402C/en not_active Expired - Fee Related
- 1990-04-27 DE DE69010199T patent/DE69010199T2/de not_active Expired - Fee Related
- 1990-04-27 US US07/768,325 patent/US5380656A/en not_active Expired - Fee Related
- 1990-04-27 NZ NZ233475A patent/NZ233475A/xx unknown
- 1990-04-27 IL IL9422790A patent/IL94227A/en not_active IP Right Cessation
- 1990-04-27 MX MX2050390A patent/MX20503A/es unknown
- 1990-04-27 EP EP90906939A patent/EP0470136B1/en not_active Expired - Lifetime
- 1990-04-27 DK DK90906939.5T patent/DK0470136T3/da active
- 1990-04-27 ES ES90906939T patent/ES2055427T3/es not_active Expired - Lifetime
- 1990-04-27 KR KR1019910701462A patent/KR920701241A/ko not_active Application Discontinuation
- 1990-04-27 HU HU903342A patent/HUT58345A/hu unknown
- 1990-04-27 PL PL90284970A patent/PL166810B1/pl unknown
- 1990-04-27 RU SU905010237A patent/RU2074891C1/ru active
- 1990-04-27 AU AU55472/90A patent/AU631641B2/en not_active Ceased
- 1990-04-27 WO PCT/EP1990/000647 patent/WO1990013561A1/en active IP Right Grant
- 1990-04-27 PT PT93921A patent/PT93921B/pt not_active IP Right Cessation
- 1990-04-27 AT AT90906939T patent/ATE107660T1/de not_active IP Right Cessation
- 1990-04-27 RO RO148615A patent/RO112032B1/ro unknown
- 1990-04-27 DD DD90340234A patent/DD296960A5/de not_active IP Right Cessation
- 1990-04-29 EG EG24990A patent/EG19583A/xx active
- 1990-05-04 YU YU87090A patent/YU87090A/sh unknown
-
1991
- 1991-10-23 FI FI914995A patent/FI914995A0/fi unknown
- 1991-10-24 BG BG95362A patent/BG60916B1/bg unknown
- 1991-10-25 NO NO91914206A patent/NO914206L/no unknown
- 1991-11-25 IN IN873MA1991 patent/IN173230B/en unknown
-
1993
- 1993-04-02 HR HR930700A patent/HRP930700A2/hr not_active Application Discontinuation
- 1993-06-19 LV LVP-93-624A patent/LV10200B/xx unknown
- 1993-12-21 LT LTIP1645A patent/LT3827B/lt not_active IP Right Cessation
-
1994
- 1994-09-08 US US08/302,369 patent/US5468480A/en not_active Expired - Fee Related
-
1995
- 1995-06-30 HU HU95P/P00687P patent/HU211746A9/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DD296960A5 (de) | Therapreutisches mittel | |
| DE68922491T2 (de) | Monoklonale antikörper gegen protein c. | |
| DE3486423T3 (de) | Neue Faktor VIII Polypeptidkoagulantien | |
| EP1074616B1 (de) | Verfahren zur Reindarstellung des Proenzyms der den Blutgerinnungsfaktor VII aktivierenden Protease mittels Ionenaustauscherchromatographie | |
| JP2001086984A (ja) | アフィニティークロマトグラフィーによって血液凝固第ｖｉｉ因子を活性化するプロテアーゼ、そのプロ酵素または両タンパク質の混合物を純粋形態で調製する方法 | |
| DE68929388T2 (de) | Aus Harn isolierte antikoagulierende Verbindung | |
| EP1012191B1 (de) | VERFAHREN ZUR GEWINNUNG VON HOCHREINEM vWF ODER FACTOR VIII/vWF-KOMPLEX | |
| DE69011531T2 (de) | Von faktor vii abgeleitete peptide mit antihämostatischer wirkung. | |
| DE69635977T2 (de) | Verfahren zur Bestimmung der therapeutischen Wirkung von Metalloproteinase-Verbindungen, neue Inhibitor-Verbindungen und deren therapeutische Verwendung | |
| JPH09503775A (ja) | 治療に使用するためのインター−α−トリプシンインヒビター濃縮物の調製方法、およびそのようにして得られる濃縮物 | |
| JP2003501012A (ja) | ボツリヌス菌毒素ｂ及び破傷風菌神経毒素の特異的阻害剤及び治療薬としてのプレビン類 | |
| DE69827223T2 (de) | Antiangiogene substanz zur behandlung von krebs, arthritis und netzhauterkrankungen | |
| DE3689927T2 (de) | Reagens und Verfahren. | |
| DE3486023T2 (de) | Verfahren zur herstellung von urokinase zymogen. | |
| EP0182906A1 (en) | Human leukocyte elastase inhibitors prepared from pyogenic bacteria and methods for their purification | |
| EP0227827A1 (de) | Undulin und dessen fragmentierungsprodukte, verfahren zu deren herstellung und ihre verwendung | |
| AT404359B (de) | Gereinigte multimerase | |
| Peanasky et al. | Proteinase inhibitors from Ascaris lumbricoides: Properties and their physiological role | |
| AU781741B2 (en) | Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or mixture of both proteins by means of ion-exchange chromatography | |
| AT404554B (de) | Pharmazeutische präparation | |
| DE3804590A1 (de) | Diagnostische sonden zum nachweis von elastase-modifiziertem antithrombin und verfahren zur behandlung | |
| EP0263529A1 (de) | Faktor-IX-Peptide | |
| DE3339693A1 (de) | Homologe des aprotinin mit anderen aminosaeuren in position 15 anstelle von lysin, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |